Lada Leyens

Senior Director, EUCAN regulatory head GI Takeda

Lada Leyens has a background in human genetics, health economics and personalised medicine. She has worked at Health Authorities for over 8 years, mainly in the approval of clinical trials and as a GCP inspector at Swissmedic. At EMA she was in the specialised disciplines office working in the centralised procedure and with the PKWP and PGWP. At Roche, Lada was the Regulatory Lead for digital health programs and the Regulatory Shaping Lead on Clinical Trial Innovation. At Takeda, she leads the therapeutic are of GI and Inflammation for the EUCAN region and is vice-chair of EFPIA-CREG. Lada is passionate about leveraging innovative technologies to make drug development more efficient and bringing innovative drugs faster to patients.

See Lada Leyens at this event

Webinar 4 Tuesday 25 November

Streamlining regulatory and ethics approvals

13:00 - 13:55 CET

Research capacity activities in clinical trials

Caxton Murira, Science for Africa Foundation

Reliance in clinical trials

Lada Leyens, Takeda on behalf of IFPMA

A digital platform for clinical trial approval

Adriaan Kruger & Marina Lazaridis, nuvoteQ Foundation

Moderated Panel Session

Kwasi Nyarko, AVAREF
David Mukanga, Gates Foundation
Elvis Temfack, Africa CDC
Caroline Macharia, J&J
Angelika Joos, MSD on behalf of IFPMA
Keymanthri Moodley, Emeritus Professor – Stellenbosch University, SA & Adjunct Professor, University of North Carolina-Chapel Hill, USA

Speakers

Speakers